Free Trial

111 Q3 2023 Earnings Report

111 logo
$10.08 -0.13 (-1.27%)
As of 03:59 PM Eastern

111 EPS Results

Actual EPS
-$1.60
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

111 Revenue Results

Actual Revenue
$502.36 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

111 Announcement Details

Quarter
Q3 2023
Time
N/A

Conference Call Resources

Remove Ads

111 Earnings Headlines

111 (NASDAQ:YI) Earns "Sell (D-)" Rating from Weiss Ratings
A brutally honest economic warning for 2025 (see proof)
New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked side-by-side with figures like Warren Buffett, Alan Greenspan, Ron Paul, Jim Rickards, and Steve Forbes, to name but a few) says....
111, Inc. (YI) Q4 2024 Earnings Call Transcript
See More 111 Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like 111? Sign up for Earnings360's daily newsletter to receive timely earnings updates on 111 and other key companies, straight to your email.

About 111

111 (NASDAQ:YI) engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies. The B2B segment includes the sale of pharmaceutical products to pharmacy customers through 1 Drug Mall. The company was founded by Gang Yu and Jun Ling Liu in May 2013 and is headquartered in Shanghai, China.

View 111 Profile

More Earnings Resources from MarketBeat